Organogenesis Holdings Inc. (ORGO)
| Market Cap | 223.89M -63.5% |
| Revenue (ttm) | 457.45M +6.5% |
| Net Income | -101.68M |
| EPS | -0.80 |
| Shares Out | 128.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 358,927 |
| Open | 1.730 |
| Previous Close | 1.740 |
| Day's Range | 1.700 - 1.750 |
| 52-Week Range | 1.540 - 7.077 |
| Beta | 1.32 |
| Analysts | Hold |
| Price Target | 2.00 (+14.94%) |
| Earnings Date | Aug 6, 2026 |
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ORGO stock is "Hold." The 12-month stock price target is $2.0, which is an increase of 14.94% from the latest price.
News
Organogenesis price target lowered to $2 from $3 at Truist
Truist analyst Ravi Misra lowered the firm’s price target on Organogenesis (ORGO) to $2 from $3 and keeps a Hold rating on the shares.
Organogenesis Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw a 58% revenue decline year-over-year due to CMS-driven market contraction, but sequential growth and market share gains were achieved through evidence-based products. Revised 2026 guidance anticipates a 62%–68% revenue drop, with cost reductions and positive adjusted EBITDA expected in Q4.
Organogenesis Holdings Earnings release: Q2 2026
Organogenesis Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Organogenesis Holdings Quarterly report: Q2 2026
Organogenesis Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de...
Organogenesis Affinity meets primary endpoint in complex venous leg ulcer trial
Organogenesis (ORGO) published results from a prospective, multicenter, randomized controlled trial evaluating Affinity plus standard of care compared to standard of care alone in the management of co...
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgic...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de...
Organogenesis announces FDA acceptance of ReNu biologics license application
Organogenesis (ORGO) announced that the FDA has completed their filing determination and accepted for review the company’s biologics license application, or BLA, for ReNu, a cryopreserved, amniotic su...
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgic...
Organogenesis Holdings Transcript: AGM 2026
The meeting covered director elections, executive compensation approval, and auditor ratification, with all proposals passing by the required votes. No additional shareholder proposals were raised, and no questions were submitted during the Q&A session.
Organogenesis initiated with a Hold at Truist
Truist initiated coverage of Organogenesis (ORGO) with a Hold rating and $3 price target Reimbursement changes are driving structural shifts across care settings in 2026 and a shakeout in the…
Organogenesis downgraded to Neutral from Buy at BTIG
BTIG downgraded Organogenesis (ORGO) to Neutral from Buy without a price target following the Q1 report. The company’s Advanced Wound Care recovery is taking longer to play out with limited…
Organogenesis Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw a 58% revenue decline, mainly from advanced wound care, due to CMS policy changes and market disruption. Despite this, market share improved, restructuring was implemented, and key regulatory milestones were achieved. Sequential recovery and profitability are expected by Q4.
Organogenesis Holdings Earnings release: Q1 2026
Organogenesis Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Organogenesis Holdings Quarterly report: Q1 2026
Organogenesis Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the dev...
Organogenesis Holdings Proxy statement: Proxy filing
Organogenesis Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Organogenesis completes rolling submission of ReNu BLA
Organogenesis (ORGO) announced the completion of a rolling biologics license application, or BLA, submission to the FDA for ReNu, a cryopreserved, amniotic suspension allograft developed for the manag...
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain
Why is Organogenesis Stock (ORGO) Up 20% Today?
Shares in regenerative medicine company Organogenesis ($ORGO) strode 20% higher in pre-market trading today after a successful trial of its foot ulcer treatment. Non-Healing Ulcers The company, which ...
Organogenesis achieves primary endpoint in PuraPly study
The company states: “Organogenesis (ORGO) Holdings announced the completion of a randomized controlled trial evaluating PuraPly(R)AM plus standard of care versus SOC alone in the management of non-hea...
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of p...
Organogenesis announces successful FDA meeting, plans to file BLA for ReNu
Organogenesis (ORGO) announced the successful completion of a planned Type-B meeting with the FDA resulting in confirmation to initiate a rolling Biologics Licenses Application for ReNu planned before...
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...